GB9200420D0
(en)
|
1992-01-09 |
1992-02-26 |
James Black Foundation The Lim |
Amino acid derivatives
|
WO1993016982A1
(en)
|
1992-02-20 |
1993-09-02 |
James Black Foundation Limited |
Bicyclo[2.2.2.]octane derivatives as cholestocystokinin inhibitors
|
AU688316B2
(en)
|
1993-04-15 |
1998-03-12 |
Glaxo Wellcome Inc. |
1,5 benzodiazepine derivatives having CCK and/or gastrin antagonistic activity
|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
CN1087725C
(zh)
|
1994-03-25 |
2002-07-17 |
同位素技术有限公司 |
用氘代方法增强药物效果
|
RU2152939C1
(ru)
|
1994-04-14 |
2000-07-20 |
Глаксо Веллкам Инк. |
5-гетероцикло-1,5-бензодиазепины и их фармацевтически приемлемые соли
|
PE27497A1
(es)
|
1994-04-15 |
1997-08-07 |
Glaxo Inc |
Derivados de 1,5 benzodiazepina
|
EP0755394A1
(en)
|
1994-04-15 |
1997-01-29 |
Glaxo Wellcome Inc. |
A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
|
FR2723739B1
(fr)
|
1994-08-19 |
1997-02-14 |
Sanofi Sa |
Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
|
GB9420763D0
(en)
|
1994-10-14 |
1994-11-30 |
Glaxo Inc |
Acetamide derivatives
|
GB9420747D0
(en)
|
1994-10-14 |
1994-11-30 |
Glaxo Inc |
1,5 benzodiazepine derivatives
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
EP2218734B1
(en)
|
1996-04-12 |
2013-06-05 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 analogs
|
FR2763337B1
(fr)
|
1997-05-13 |
1999-08-20 |
Sanofi Sa |
Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
|
CO4970713A1
(es)
|
1997-09-19 |
2000-11-07 |
Sanofi Synthelabo |
Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
|
AR022044A1
(es)
|
1999-05-06 |
2002-09-04 |
Glaxo Group Ltd |
Derivados de 1,5-benzodiazepina
|
IL155055A0
(en)
|
2000-10-26 |
2003-10-31 |
Sanofi Synthelabo |
Triazole derivatives and pharmaceutical compositions comprising them
|
HUP0004741A2
(hu)
|
2000-11-28 |
2002-12-28 |
Sanofi-Synthelabo |
Kémiai eljárás tiazolszármazékok előállítására és új intermedier
|
JP4280070B2
(ja)
|
2001-02-16 |
2009-06-17 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド2(glp−2)
|
EP1369698A1
(en)
|
2002-06-07 |
2003-12-10 |
Bayer Ag |
Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (SSTR5)
|
AU2003288956A1
(en)
*
|
2002-10-30 |
2004-06-07 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of rock and other protein kinases
|
WO2005035793A2
(en)
|
2003-10-09 |
2005-04-21 |
Decode Genetics Ehf. |
Cckar markers and haplotypes associated with extreme weight conditions
|
WO2005051890A1
(en)
|
2003-11-19 |
2005-06-09 |
Smithkline Beecham Corporation |
Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
|
JP4859665B2
(ja)
|
2004-03-30 |
2012-01-25 |
武田薬品工業株式会社 |
アルコキシフェニルプロパン酸誘導体
|
CA2568056A1
(en)
|
2004-05-25 |
2005-12-08 |
Pfizer Products Inc. |
Tetraazabenzo[e]azulene derivatives and analogs thereof
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
WO2006083612A1
(en)
|
2005-01-28 |
2006-08-10 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
AU2006210954A1
(en)
|
2005-01-31 |
2006-08-10 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
US20060177438A1
(en)
|
2005-02-08 |
2006-08-10 |
New England Medical Center |
Methods of altering absorption of hydrophobic compounds
|
EP2295451A1
(en)
|
2005-05-04 |
2011-03-16 |
Zealand Pharma A/S |
Glucagon-like-peptide (GLP-2) analogues
|
CA2608819A1
(en)
|
2005-06-02 |
2006-12-07 |
F. Hoffmann-La Roche Ag |
Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists
|
EP1948785B1
(en)
|
2005-10-24 |
2014-01-15 |
Janssen Biotech, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
US20090313709A1
(en)
|
2006-01-31 |
2009-12-17 |
Yoshihiko Kaisho |
Genetically Modified Animal and Use Thereof
|
JP5155999B2
(ja)
|
2006-04-14 |
2013-03-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
コレシストキニン−1受容体モジュレーターとしての置換イミダゾール−4−カルボキサミド
|
DE602007008868D1
(de)
|
2006-04-14 |
2010-10-14 |
Merck Sharp & Dohme |
Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
|
TW200815377A
(en)
|
2006-04-24 |
2008-04-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
EP2021327B1
(en)
|
2006-05-15 |
2012-04-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2008028117A2
(en)
|
2006-08-31 |
2008-03-06 |
Centocor, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
WO2008063768A2
(en)
|
2006-10-12 |
2008-05-29 |
Case Western Reserve University |
Compositions and methods for treating metabolic diseases
|
WO2008054675A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
WO2008054674A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
EA023886B1
(ru)
|
2006-11-08 |
2016-07-29 |
Зеаланд Фарма А/С |
Селективные аналоги глюкагонподобного пептида-2 (glp-2)
|
US7750048B2
(en)
|
2006-11-15 |
2010-07-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists
|
AU2007325315A1
(en)
|
2006-11-28 |
2008-06-05 |
Kalypsys Inc |
Heterocyclic modulators of TGR5
|
US20090035306A1
(en)
|
2006-11-29 |
2009-02-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
CA2676417C
(en)
|
2007-01-19 |
2016-06-28 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
US20100113492A1
(en)
|
2007-01-26 |
2010-05-06 |
Merck & Co., Inc. |
Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators
|
US20080221161A1
(en)
|
2007-02-09 |
2008-09-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
US20090105124A1
(en)
|
2007-08-23 |
2009-04-23 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
JP2010539152A
(ja)
|
2007-09-10 |
2010-12-16 |
プロシディオン・リミテッド |
代謝障害の治療のための化合物
|
AU2008302570B2
(en)
|
2007-09-20 |
2012-05-31 |
Irm Llc |
Compounds and compositions as modulators of GPR119 activity
|
NZ584049A
(en)
|
2007-09-21 |
2011-05-27 |
Sanofi Aventis |
(carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
|
RU2010115747A
(ru)
|
2007-09-21 |
2011-10-27 |
Санофи-Авентис (Fr) |
(циклопропилфенил)фенилоксаламиды, способ их получения и их применения в качестве лекарственного средства
|
ES2401233T3
(es)
|
2007-10-17 |
2013-04-18 |
Universidad de Córdoba |
Isoformas del receptor tipo 5 de somatostatina humana producidas por tratamiento alternativo y pares de oligonucleótidos para la detección de las mismas por PCR
|
JP2011016722A
(ja)
|
2007-10-23 |
2011-01-27 |
Astellas Pharma Inc |
チアゾリジンジオン化合物
|
TW200932219A
(en)
|
2007-10-24 |
2009-08-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
US8304547B2
(en)
|
2007-10-24 |
2012-11-06 |
Astellas Pharma Inc. |
Azolecarboxamide compound or salt thereof
|
BRPI0818687A2
(pt)
|
2007-10-26 |
2017-05-02 |
Japan Tobacco Inc |
composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
|
CA2703217A1
(en)
|
2007-10-29 |
2009-05-07 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2009106565A1
(en)
*
|
2008-02-27 |
2009-09-03 |
Biovitrum Ab (Publ) |
Agonists of gpr119
|
JP5665160B2
(ja)
|
2008-03-26 |
2015-02-04 |
パナソニックIpマネジメント株式会社 |
発光装置および照明器具
|
EP2271619A1
(en)
|
2008-04-07 |
2011-01-12 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
GB0812648D0
(en)
*
|
2008-07-10 |
2008-08-20 |
Prosidion Ltd |
Compounds
|
WO2010014739A2
(en)
|
2008-07-29 |
2010-02-04 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
WO2010014836A2
(en)
|
2008-07-30 |
2010-02-04 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
WO2010016846A1
(en)
|
2008-08-08 |
2010-02-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
EP2337585A1
(en)
|
2008-09-19 |
2011-06-29 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
CA2743489A1
(en)
|
2008-11-17 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
CN106380502A
(zh)
|
2008-11-19 |
2017-02-08 |
英特塞普特医药品公司 |
G蛋白偶联受体5(tgr5)调节剂及其使用方法
|
EP2376519B1
(en)
|
2008-11-19 |
2013-11-13 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and method of use thereof
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
JP2012515782A
(ja)
|
2009-01-23 |
2012-07-12 |
シェーリング コーポレイション |
抗糖尿病性架橋および縮合化合物
|
AU2010206786A1
(en)
|
2009-01-23 |
2011-07-28 |
Merck Sharp & Dohme Corp. |
Bridged and fused heterocyclic antidiabetic compounds
|
AU2010206783A1
(en)
|
2009-01-23 |
2011-07-28 |
Merck Sharp & Dohme Corp. |
Pentafluorosulpholane-containing antidiabetic compounds
|
AR075051A1
(es)
|
2009-02-05 |
2011-03-02 |
Schering Corp |
Compuestos antidiabeticos que contienen ftalazina
|
JP2012517479A
(ja)
|
2009-02-12 |
2012-08-02 |
エグゼリクシス, インコーポレイテッド |
糖尿病および肥満の処置においてtgr5アゴニストとして使用するためのトリアゾールおよびイミダゾール誘導体
|
JP5657518B2
(ja)
|
2009-02-18 |
2015-01-21 |
武田薬品工業株式会社 |
縮合複素環化合物
|
EP2423176A4
(en)
|
2009-04-22 |
2012-11-07 |
Astellas Pharma Inc |
CARBOXYLIC ACID COMPOUND
|
JP2012136438A
(ja)
|
2009-04-22 |
2012-07-19 |
Astellas Pharma Inc |
テトラゾール化合物
|
WO2010143733A1
(en)
|
2009-06-09 |
2010-12-16 |
Takeda Pharmaceutical Company Limited |
Novel fused cyclic compound and use thereof
|
AR078522A1
(es)
|
2009-10-15 |
2011-11-16 |
Lilly Co Eli |
Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
|
EP2314616A1
(en)
|
2009-10-23 |
2011-04-27 |
Ferring B.V. |
Peptidic GLP-2 agonists
|
CA2779398A1
(en)
|
2009-10-30 |
2011-05-05 |
Mochida Phamaceutical Co., Ltd. |
Novel 3-hydroxy-5-arylisoxazole derivative
|
AR078948A1
(es)
|
2009-11-30 |
2011-12-14 |
Lilly Co Eli |
Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
|
CN102781922A
(zh)
|
2009-12-11 |
2012-11-14 |
埃克塞利希斯股份有限公司 |
Tgr5激动剂
|
CN102712610B
(zh)
|
2009-12-25 |
2015-03-04 |
持田制药株式会社 |
新的3-羟基-5-芳基异噻唑衍生物
|
AU2011256444B2
(en)
|
2010-05-18 |
2014-07-10 |
Merck Sharp & Dohme Corp. |
Spiro isoxazoline compounds as SSTR5 antagonists
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
WO2012011125A1
(en)
|
2010-07-23 |
2012-01-26 |
Connexios Life Sciences Pvt. Ltd. |
Agonists of gpr40
|
EP2605658B1
(en)
|
2010-08-18 |
2016-03-23 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
JP5908478B2
(ja)
|
2010-08-30 |
2016-04-26 |
エヌピーエス ファーマシューティカルズ インコーポレイテッドNps Pharmaceuticals, Inc. |
h「Gly2」GLP−2の固相合成
|
US9040525B2
(en)
|
2010-10-08 |
2015-05-26 |
Mochida Pharmaceutical Co., Ltd. |
Cyclic amide derivative
|
WO2012070554A1
(ja)
|
2010-11-22 |
2012-05-31 |
国立大学法人京都大学 |
ペプチド
|
DK2646425T3
(en)
|
2010-12-01 |
2015-08-24 |
Boehringer Ingelheim Int |
Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome.
|
WO2012082947A1
(en)
|
2010-12-16 |
2012-06-21 |
Irm Llc |
Compounds and compositions as tgr5 agonists
|
SG192645A1
(en)
|
2011-02-17 |
2013-09-30 |
Takeda Pharmaceutical |
Production method of optically active dihydrobenzofuran derivative
|
WO2012138919A2
(en)
|
2011-04-08 |
2012-10-11 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
EP2693882B1
(en)
*
|
2011-04-08 |
2017-06-28 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
NZ617409A
(en)
|
2011-04-27 |
2015-08-28 |
Mochida Pharm Co Ltd |
Novel 3-hydroxyisothiazole 1-oxide derivative
|
CN103619817A
(zh)
|
2011-04-28 |
2014-03-05 |
百时美施贵宝公司 |
新颖的二环含氮杂芳基tgr5受体调节剂
|
WO2012173917A1
(en)
*
|
2011-06-16 |
2012-12-20 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
WO2013054338A1
(en)
|
2011-07-06 |
2013-04-18 |
Cadila Healthcare Limited |
2-thio-imidazole derivatives as tgr5 modulators
|
TWI537262B
(zh)
|
2011-08-17 |
2016-06-11 |
美國禮來大藥廠 |
供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
|
BR112014005744B1
(pt)
|
2011-09-12 |
2020-11-17 |
Amunix Operating Inc. |
proteína de fusão recombinante, composição farmacêutica compreendendo a referida proteína e uso da mesma referência cruzada com pedido relacionado
|
WO2013057743A1
(en)
|
2011-10-21 |
2013-04-25 |
Connexios Life Sciences Pvt. Ltd |
Process for the preparation of an aryl oxime and salts thereof
|
WO2013074388A1
(en)
*
|
2011-11-15 |
2013-05-23 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
IN2014MN01433A
(pt)
|
2011-12-21 |
2015-07-03 |
Ardelyx Inc |
|
CN103429581B
(zh)
|
2012-01-12 |
2015-08-26 |
江苏恒瑞医药股份有限公司 |
多环类衍生物、其制备方法及其在医药上的应用
|
GB2498976A
(en)
*
|
2012-02-01 |
2013-08-07 |
Prosidion Ltd |
GPR119 agonists useful in the treatment of type II diabetes
|
JP6121339B2
(ja)
|
2012-02-13 |
2017-04-26 |
武田薬品工業株式会社 |
芳香環化合物
|
US9382188B2
(en)
|
2012-02-13 |
2016-07-05 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound
|
WO2013128378A1
(en)
|
2012-02-28 |
2013-09-06 |
Piramal Enterprises Limited |
Phenyl alkanoic acid derivatives as gpr agonists
|
US8642585B2
(en)
|
2012-03-26 |
2014-02-04 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
WO2013154163A1
(ja)
|
2012-04-11 |
2013-10-17 |
持田製薬株式会社 |
新規5-アリール-1,2-チアジナン誘導体
|
US8809376B2
(en)
|
2012-04-30 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
AU2013255752B2
(en)
|
2012-05-03 |
2017-11-09 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (GLP-2) analogues
|
US8633182B2
(en)
|
2012-05-30 |
2014-01-21 |
Boehringer Ingelheim International Gmbh |
Indanyloxyphenylcyclopropanecarboxylic acids
|
WO2014019186A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
EP2900242A4
(en)
*
|
2012-09-26 |
2016-06-29 |
Merck Sharp & Dohme |
SUBSTITUTED CYCLOPROPYL COMPOUNDS
|
US9777038B2
(en)
|
2012-10-26 |
2017-10-03 |
Intercept Pharmaceuticals, Inc. |
Process for preparing bile acid derivatives
|
TWI692469B
(zh)
|
2012-11-09 |
2020-05-01 |
南韓商Lg化學股份有限公司 |
Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
|
RU2693382C2
(ru)
|
2012-11-28 |
2019-07-02 |
Интерсепт Фармасьютикалз, Инк. |
Лечение заболевания дыхательной системы
|
KR20150088878A
(ko)
|
2012-11-28 |
2015-08-03 |
베링거 인겔하임 인터내셔날 게엠베하 |
신규한 인다닐옥시디하이드로벤조푸라닐아세트산
|
JP6283862B2
(ja)
|
2012-12-07 |
2018-02-28 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規インダニルオキシジヒドロベンゾフラニル酢酸
|
WO2014100021A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
|
WO2014100025A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists having an imidazole or triazole core with subtituent having a quaternary nitrogen
|
WO2014096440A2
(en)
|
2012-12-21 |
2014-06-26 |
Novozymes Biopharma Dk A/S |
Composition
|
WO2014122067A1
(en)
|
2013-02-06 |
2014-08-14 |
Boehringer Ingelheim International Gmbh |
New indanyloxydihydrobenzofuranylacetic acids
|
US9840512B2
(en)
|
2013-02-22 |
2017-12-12 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
CN104059039B
(zh)
|
2013-03-22 |
2017-03-15 |
正大天晴药业集团股份有限公司 |
具有gpr40受体功能调节作用的稠环化合物
|
CN104109115B
(zh)
|
2013-04-16 |
2016-11-23 |
中国科学院上海药物研究所 |
一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
|
WO2014170842A2
(en)
|
2013-04-17 |
2014-10-23 |
Piramal Enterprises Limited |
Substituted alkyl carboxylic acid derivatives as gpr agonists
|
CN104870429B
(zh)
|
2013-05-22 |
2017-05-03 |
四川海思科制药有限公司 |
苯并呋喃衍生物、其制备方法及其在医药上的应用
|
KR20160034893A
(ko)
|
2013-06-13 |
2016-03-30 |
패스트 포워드 파머슈티컬스 비.브이. |
Cd40 시그널링 억제제 및 추가 화합물로서, 상기 추가 화합물은 담즙산, 담즙산 유도체, tgr5-수용체 아고니스트, fxr 아고니스트 또는 이들의 조합이고, 만성 염증의 치료용, 및 위장 암 또는 섬유증의 예방용인, cd40 시그널링 억제제 및 추가 화합물
|
WO2015000412A1
(zh)
|
2013-07-02 |
2015-01-08 |
四川海思科制药有限公司 |
苯并环丁烯类衍生物、其制备方法及其在医药上的应用
|
CN105143181B
(zh)
|
2013-07-26 |
2017-12-26 |
四川海思科制药有限公司 |
三元并环羧酸类衍生物、其制备方法及其在医药上的应用
|
PL3027642T3
(pl)
|
2013-07-31 |
2021-01-11 |
Amgen Inc. |
Konstrukty czynnika różnicowania wzrostu 15 (GDF-15)
|
EP3031799B1
(en)
|
2013-08-09 |
2018-04-04 |
Takeda Pharmaceutical Company Limited |
Aromatic compound
|
CN104418801B
(zh)
|
2013-08-19 |
2016-10-05 |
上海润诺生物科技有限公司 |
苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
|
CN105473595A
(zh)
|
2013-08-23 |
2016-04-06 |
福建海西新药创制有限公司 |
治疗糖尿病的羧酸化合物
|
WO2015028960A1
(en)
|
2013-08-28 |
2015-03-05 |
Piramal Enterprises Limited |
Substituted heterocyclic derivatives as gpr agonists and uses thereof
|
CN105246875A
(zh)
|
2013-09-03 |
2016-01-13 |
四川海思科制药有限公司 |
茚满衍生物及其制备方法和在医药上的应用
|
WO2015044073A1
(en)
|
2013-09-26 |
2015-04-02 |
Boehringer Ingelheim International Gmbh |
Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
|
JO3442B1
(ar)
|
2013-10-07 |
2019-10-20 |
Takeda Pharmaceuticals Co |
مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015062486A1
(en)
|
2013-10-31 |
2015-05-07 |
Sunshine Lake Pharma Co., Ltd. |
Biphenyl compounds and uses thereof
|
EA201690888A1
(ru)
|
2013-11-14 |
2016-10-31 |
Кадила Хелзкэр Лимитед |
Новые гетероциклические соединения
|
ES2747973T3
(es)
|
2013-11-15 |
2020-03-12 |
Merck Sharp & Dohme |
Compuestos tricíclicos antidiabéticos
|
EP3074375B1
(en)
|
2013-11-28 |
2018-04-04 |
Boehringer Ingelheim International GmbH |
New indanyloxyphenylcyclopropanecarboxylic acids
|
US9957219B2
(en)
|
2013-12-04 |
2018-05-01 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
TW201609722A
(zh)
|
2013-12-13 |
2016-03-16 |
美國禮來大藥廠 |
新穎三唑并吡啶化合物
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
JP6211200B2
(ja)
|
2014-01-10 |
2017-10-11 |
イーライ リリー アンド カンパニー |
フェニル−トリアゾロ−ピリジン化合物
|
JP6170255B2
(ja)
|
2014-01-10 |
2017-07-26 |
イーライ リリー アンド カンパニー |
イソプロピルトリアゾロピリジン化合物
|
EP3102198B1
(en)
|
2014-02-06 |
2020-08-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic compounds
|
WO2015160772A1
(en)
|
2014-04-15 |
2015-10-22 |
Janssen Pharmaceutica Nv |
Tetrahydro-benzoimidazolyl modulators of tgr5
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US10166246B2
(en)
|
2014-05-27 |
2019-01-01 |
City Of Hope |
TGR5 agonist complexes for treating diabetes and cancer
|
MA39881B1
(fr)
|
2014-05-29 |
2020-02-28 |
Bar Pharmaceuticals S R L |
Dérivés de cholane à utiliser dans le traitement et/ou la prévention de maladies médiées par fxr et tgr5/gpbar1
|
EP3157947A1
(en)
|
2014-06-23 |
2017-04-26 |
Novartis AG |
Hsa-gdf-15 fusion polypeptide and use thereof
|
EP3164538A1
(en)
|
2014-07-02 |
2017-05-10 |
Arçelik Anonim Sirketi |
Built-in household appliance unpowered control and status indication device
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2016019587A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[7, 6]-fused bicyclic antidiabetic compounds
|
EP3177287B1
(en)
|
2014-08-08 |
2022-02-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10100042B2
(en)
|
2014-08-08 |
2018-10-16 |
Merck Sharp & Dohme Corp. |
[5,6]—fused bicyclic antidiabetic compounds
|
WO2016032120A1
(ko)
|
2014-08-27 |
2016-03-03 |
씨제이헬스케어 주식회사 |
신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
|
WO2016054208A1
(en)
|
2014-10-03 |
2016-04-07 |
Mayo Foundation For Medical Education And Research |
Targeting tgr5 to treat disease
|
TW201629033A
(zh)
|
2014-10-08 |
2016-08-16 |
健生藥品公司 |
作為治療第二型糖尿病之gpr40促效劑的經取代苯并噻吩基衍生物
|
KR101726819B1
(ko)
*
|
2014-10-27 |
2017-04-13 |
동아에스티 주식회사 |
Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
|
JP2017537894A
(ja)
|
2014-10-31 |
2017-12-21 |
グブラ エーピーエス |
Glp−1rおよびglp−2r二重アゴニスト活性を有する組成物及びペプチド
|
US10266560B2
(en)
|
2014-11-06 |
2019-04-23 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
RU2017130466A
(ru)
|
2015-02-11 |
2019-03-12 |
Энанта Фармасьютикалс, Инк. |
Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
|
ES2886766T3
(es)
|
2015-03-31 |
2021-12-20 |
Enanta Pharm Inc |
Derivados del ácido biliar como agonistas de FXR/TGR5 y métodos de uso de estos
|
TW201712012A
(zh)
|
2015-06-16 |
2017-04-01 |
美國禮來大藥廠 |
2-側氧基-1,3,8-三氮雜螺[4.5]癸-3-基羧酸衍生物
|
AU2016280806B2
(en)
|
2015-06-19 |
2021-01-28 |
Intercept Pharmaceuticals, Inc. |
TGR5 modulators and methods of use thereof
|
WO2017002786A1
(ja)
|
2015-07-02 |
2017-01-05 |
サントリーホールディングス株式会社 |
Glp-2分泌促進用組成物
|
AR105269A1
(es)
|
2015-07-06 |
2017-09-20 |
Novo Nordisk As |
Péptidos y derivados de péptidos de colecistoquinina (cck) y sus usos
|
CA2994687A1
(en)
|
2015-08-07 |
2017-02-16 |
Intercept Pharmaceuticals, Inc. |
Methods for preparation of bile acids and derivatives thereof
|
US9617251B2
(en)
|
2015-08-07 |
2017-04-11 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US9856245B2
(en)
|
2015-08-12 |
2018-01-02 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
WO2017027309A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
US9908873B2
(en)
|
2015-08-12 |
2018-03-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
EP3347358B1
(en)
|
2015-09-09 |
2019-11-27 |
Boehringer Ingelheim International GmbH |
[{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
|
EP3353189A4
(en)
|
2015-09-24 |
2019-06-19 |
Intercept Pharmaceuticals, Inc. |
METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES
|
CA3004275A1
(en)
|
2015-11-06 |
2017-05-11 |
Intercept Pharmaceuticals, Inc. |
Methods for the preparation of obeticholic acid and derivatives thereof
|
TWI773657B
(zh)
|
2015-12-18 |
2022-08-11 |
美商亞德利克斯公司 |
作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
|
US10364267B2
(en)
|
2016-02-23 |
2019-07-30 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
WO2017147137A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
|
JP2019510739A
(ja)
|
2016-02-29 |
2019-04-18 |
イーライ リリー アンド カンパニー |
Gfral受容体療法
|
WO2017172505A1
(en)
|
2016-03-29 |
2017-10-05 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10106553B2
(en)
|
2016-04-11 |
2018-10-23 |
Janssen Pharmaceutica Nv |
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
|
CA3020698A1
(en)
|
2016-04-13 |
2017-10-19 |
Intercept Pharmaceuticals, Inc. |
Methods of treating or preventing hepatocellular carcinoma
|
US11236055B2
(en)
|
2016-07-01 |
2022-02-01 |
Venenum Biodesign, LLC |
Non-systemic TGR5 agonists
|
US10654834B2
(en)
|
2016-07-01 |
2020-05-19 |
Venenum Biodesign, LLC |
Non-systemic TGR5 agonists
|
WO2018009778A1
(en)
|
2016-07-07 |
2018-01-11 |
Baylor College Of Medicine |
Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
|
WO2018064441A1
(en)
|
2016-09-30 |
2018-04-05 |
Intercept Pharmaceuticals, Inc |
Crystalline forms of a bile acid derivative
|
CA3038846A1
(en)
|
2016-10-12 |
2018-04-19 |
Janssen Biotech, Inc. |
Methods for screening for modulators of gdf15-like biological activity
|
WO2018077699A1
(en)
|
2016-10-25 |
2018-05-03 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
WO2018081047A1
(en)
|
2016-10-25 |
2018-05-03 |
Janssen Pharmaceutica Nv |
Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
|
EP3544958B1
(en)
|
2016-11-28 |
2021-03-24 |
Boehringer Ingelheim International GmbH |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
CA3044915A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
KR102007633B1
(ko)
|
2016-12-15 |
2019-08-06 |
일동제약(주) |
신규 페닐 프로피온 산 유도체 및 이의 용도
|
EP3558298A4
(en)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC SPIROCHROMAN COMPOUNDS
|
EP3573953A1
(en)
|
2017-01-26 |
2019-12-04 |
Boehringer Ingelheim International GmbH |
Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US10793530B2
(en)
|
2017-01-26 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
CN110177773B
(zh)
|
2017-01-26 |
2023-08-25 |
勃林格殷格翰国际有限公司 |
苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
|
CN110312714B
(zh)
|
2017-01-26 |
2022-12-09 |
勃林格殷格翰国际有限公司 |
苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途
|
US10253004B2
(en)
|
2017-01-26 |
2019-04-09 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
WO2018142363A1
(en)
|
2017-02-06 |
2018-08-09 |
Orbicular Pharmaceutical Technologies Private Limited |
Ready to use compositions of glp-2 analogues through self-administrable devices
|
US10550127B1
(en)
|
2017-02-08 |
2020-02-04 |
Boehringer Ingelheim International Gmbh |
Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
|
GB201704714D0
(en)
|
2017-03-24 |
2017-05-10 |
Caldan Therapeutics Ltd |
Pharmaceutical compounds
|
WO2018181847A1
(ja)
|
2017-03-31 |
2018-10-04 |
武田薬品工業株式会社 |
芳香環化合物
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
CN107162921B
(zh)
|
2017-05-27 |
2019-12-13 |
中国药科大学 |
一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
|
WO2018222701A1
(en)
|
2017-05-30 |
2018-12-06 |
Intercept Pharmaceuticals, Inc. |
Treatment of renal diseases with a bile acid derivative
|
WO2018226724A1
(en)
|
2017-06-05 |
2018-12-13 |
Intercept Pharmaceuticals, Inc. |
Treatment and prevention of diabetic eye diseases with a bile acid derivatives
|
SG11201912161SA
(en)
|
2017-06-16 |
2020-01-30 |
Zealand Pharma As |
Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
|
IL271343B2
(en)
|
2017-06-23 |
2023-12-01 |
Intercept Pharmaceuticals Inc |
Methods and intermediates for the preparation of bile acid derivatives
|
BR112020003736A2
(pt)
|
2017-08-22 |
2020-09-08 |
Shire-Nps Pharmaceuticals, Inc. |
polipeptídeos de fusão de glp-2 e usos para tratar e prevenir condições gastrointestinais
|
WO2019086559A1
(fr)
|
2017-10-31 |
2019-05-09 |
Adocia |
Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
MX2020004620A
(es)
|
2017-11-06 |
2020-10-12 |
Shire Nps Pharmaceuticals Inc |
Analogos y pepticuerpos de peptido 2 similar a glucagon (glp-2) para administracion antes, durante o despues de cirugia.
|
EP3709995A4
(en)
|
2017-11-16 |
2021-04-14 |
Merck Sharp & Dohme Corp. |
BICYCLIC ANTIDIABETIC COMPOUNDS
|
FI3737470T3
(fi)
|
2018-01-08 |
2023-03-19 |
Celon Pharma Sa |
3-fenyyli-4-heksyylihappojohdannaisia GPR40-agonisteina
|
WO2020197926A1
(en)
|
2019-03-22 |
2020-10-01 |
Kallyope, Inc. |
Gpcr combination therapies
|
EP3976576A4
(en)
|
2019-05-29 |
2023-06-28 |
Kallyope, Inc. |
Gpr40 agonists
|
EP4041722A4
(en)
*
|
2019-10-07 |
2023-12-13 |
Kallyope, Inc. |
GPR119 AGONISTS
|
US20230041621A1
(en)
|
2019-12-03 |
2023-02-09 |
Kallyope, Inc. |
Sstr5 antagonists
|
WO2021174048A1
(en)
|
2020-02-28 |
2021-09-02 |
Kallyope, Inc. |
Gpr40 agonists
|
AU2021225966A1
(en)
|
2020-02-28 |
2022-09-15 |
Kallyope, Inc. |
GPR40 agonists
|